Abstract: Objective: To evaluate the efficacy and safety of tofacitinib in the treatment of psoriatic arthritis. Methods: All randomized controlled trials (RCT) of tofacitinib in the treatment of psoriatic arthritis were searched in CNKI,Wanfang,VIP,CBM,Pubmed,Embase,The Cochrane Library. Meta analysis was performed after extracting the data. Results: Three RCTs with a total of 914 patients were included. Meta analysis results showed that the efficacy of tofacitinib 5mg group and tofacitinib 10mg group was significantly higher than that of the placebo group，including the primary outcome of ACR20, ACR50,ACR70,PASI75, dactylitis and  enthesitis inflammation remission rate（Ps＜0.05）.There was no statistical significance in the efficacy between tofacitinib 10mg group and tofacitinib 5mg group（P＞0.05）. There was no statistical significance in the incidence of any adverse event,serious adverse event,serious infection,herpes zoster infectionsand opportunistic infection（Ps＞0.05）between tofacitinib group and placebo group. There was no statistical significance in the incidence of adverse eventbetween tofacitinib 10mg group and tofacitinib 5mg group（P＞0.05）. Conclusion: Tofacitinib is effective and safe in the treatment of psoriatic arthritis.

Key words: tofacitinib , psoriatic arthritis , randomized controlled trials ;meta analysis